Cargando…

COG5-CDG: expanding the clinical spectrum

BACKGROUND: The Conserved Oligomeric Golgi (COG) complex is involved in the retrograde trafficking of Golgi components, thereby affecting the localization of Golgi glycosyltransferases. Deficiency of a COG-subunit leads to defective protein glycosylation, and thus Congenital Disorders of Glycosylati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rymen, Daisy, Keldermans, Liesbeth, Race, Valérie, Régal, Luc, Deconinck, Nicolas, Dionisi-Vici, Carlo, Fung, Cheuk-wing, Sturiale, Luisa, Rosnoblet, Claire, Foulquier, François, Matthijs, Gert, Jaeken, Jaak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697985/ https://www.ncbi.nlm.nih.gov/pubmed/23228021 http://dx.doi.org/10.1186/1750-1172-7-94

Ejemplares similares

Correction: COG5-CDG: expanding the clinical spectrum
por: Rymen, Daisy, et al.
Publicado: (2013)

COG6‐CDG: Novel variants and novel malformation
por: Cirnigliaro, Lara, et al.
Publicado: (2022)

SLC37A4‐CDG: Second patient
por: Wilson, Matthew P., et al.
Publicado: (2021)

CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking
por: Wilson, Matthew P, et al.
Publicado: (2022)

SLC35A2-CDG: Novel variant and review
por: Quelhas, Dulce, et al.
Publicado: (2021)

MAN1B1 Deficiency: An Unexpected CDG-II
por: Rymen, Daisy, et al.
Publicado: (2013)

ALG11-CDG: Three novel mutations and further characterization of the phenotype
por: Regal, L., et al.
Publicado: (2014)

Golgi function and dysfunction in the first COG4-deficient CDG type II patient
por: Reynders, Ellen, et al.
Publicado: (2009)

A novel mutation and first report of dilated cardiomyopathy in ALG6-CDG (CDG-Ic): a case report
por: Al-Owain, Mohammed, et al.
Publicado: (2010)

PMM2‐CDG and nephrotic syndrome: A case report
por: Banderali, Giuseppe, et al.
Publicado: (2022)

How to find and diagnose a CDG due to defective N-glycosylation
por: Lefeber, Dirk J., et al.
Publicado: (2011)

Neonatal presentation of COG6‐CDG with prominent skin phenotype
por: Komlosi, Katalin, et al.
Publicado: (2020)

Genotype-Phenotype Correlations in PMM2-CDG
por: Vaes, Laurien, et al.
Publicado: (2021)

CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)

Congenital disorders of glycosylation (CDG): state of the art in 2022
por: Francisco, Rita, et al.
Publicado: (2023)

Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG)
por: Pettinato, Fabio, et al.
Publicado: (2021)

ALG8-CDG: novel patients and review of the literature
por: Höck, Michaela, et al.
Publicado: (2015)

The Swedish COG6‐CDG experience and a comprehensive literature review
por: Xia, Zhi‐Jie, et al.
Publicado: (2022)

Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1‐CDG)
por: Altassan, Ruqaiah, et al.
Publicado: (2022)

Ophthalmological and electrophysiological findings in monozygotic twin sisters with phosphomannomutase 2 deficiency (PMM2-CDG) over a period of 37 years
por: Van Hees, Ines, et al.
Publicado: (2019)

Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases
por: Sumya, Farhana Taher, et al.
Publicado: (2021)

ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG
por: Wong, Sunnie Yan-Wai, et al.
Publicado: (2017)

SRD5A3 defective congenital disorder of glycosylation: clinical utility gene card
por: Jaeken, Jaak, et al.
Publicado: (2020)

Hypoglycemia in CDG patients due to PMM2 mutations: Follow up on hyperinsulinemic patients
por: Moravej, Hossein, et al.
Publicado: (2019)

Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016)

Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG)
por: Brasil, Sandra, et al.
Publicado: (2022)

Correction: Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016)

D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial
por: Witters, Peter, et al.
Publicado: (2021)

New Insights into Immunological Involvement in Congenital Disorders of Glycosylation (CDG) from a People-Centric Approach
por: Francisco, Rita, et al.
Publicado: (2020)

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
por: Serrano, Mercedes, et al.
Publicado: (2015)

GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients
por: de la Morena-Barrio, Maria E, et al.
Publicado: (2013)

Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
por: Lebredonchel, Elodie, et al.
Publicado: (2021)

A PMM2-CDG caused by an A108V mutation associated with a heterozygous 70 kilobases deletion case report
por: Lebredonchel, E., et al.
Publicado: (2022)

Nijmegen paediatric CDG rating scale: a novel tool to assess disease progression
por: Achouitar, Samira, et al.
Publicado: (2011)

CDG – an update
por: Morava, Eva, et al.
Publicado: (2011)

Clinical, molecular and glycophenotype insights in SLC39A8-CDG
por: Bonaventura, Eleonora, et al.
Publicado: (2021)

SRD5A3-CDG: Emerging Phenotypic Features of an Ultrarare CDG Subtype
por: Kamarus Jaman, Nazreen, et al.
Publicado: (2021)

Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis
por: Sturiale, Luisa, et al.
Publicado: (2021)

Congenital Disorders of Glycosylation: A Multi-genetic Disease Family with Multiple Subcellular Locations
por: Jaeken, Jaak
Publicado: (2020)

Mannose supplementation in PMM2-CDG
por: Taday, Roman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3t8eob0h8m1c8pmvgr2r9eff5b